These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38160638)

  • 1. Prognostic value of cerebrospinal fluid biomarkers in multiple sclerosis: The key role of kappa free light chains and a multivariate predictor for disease progression.
    Miklušová M; Fürst T; Zimek D; Mareš J
    Mult Scler Relat Disord; 2024 Feb; 82():105402. PubMed ID: 38160638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of free light chains lambda and kappa in early multiple sclerosis.
    Voortman MM; Stojakovic T; Pirpamer L; Jehna M; Langkammer C; Scharnagl H; Reindl M; Ropele S; Seifert-Held T; Archelos JJ; Fuchs S; Enzinger C; Fazekas F; Khalil M
    Mult Scler; 2017 Oct; 23(11):1496-1505. PubMed ID: 27899552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic and Prognostic Value of the Cerebrospinal Fluid Concentration of Immunoglobulin Free Light Chains in Clinically Isolated Syndrome with Conversion to Multiple Sclerosis.
    Makshakov G; Nazarov V; Kochetova O; Surkova E; Lapin S; Evdoshenko E
    PLoS One; 2015; 10(11):e0143375. PubMed ID: 26606531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid kappa and lambda free light chains in oligoclonal band-negative patients with suspected multiple sclerosis.
    Ferraro D; Trovati A; Bedin R; Natali P; Franciotta D; Santangelo M; Camera V; Vitetta F; Varani M; Trenti T; Gastaldi M; De Biasi S; Nasi M; Pinti M; Meletti S; Sola P
    Eur J Neurol; 2020 Mar; 27(3):461-467. PubMed ID: 31710409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kappa free light chains could predict early disease course in multiple sclerosis.
    Vecchio D; Crespi I; Virgilio E; Naldi P; Campisi MP; Serino R; Dianzani U; Bellomo G; Cantello R; Comi C
    Mult Scler Relat Disord; 2019 May; 30():81-84. PubMed ID: 30738877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid kappa free light chains as biomarker in multiple sclerosis-from diagnosis to prediction of disease activity.
    Hegen H; Berek K; Deisenhammer F
    Wien Med Wochenschr; 2022 Nov; 172(15-16):337-345. PubMed ID: 35133530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis.
    Hegen H; Walde J; Berek K; Arrambide G; Gnanapavan S; Kaplan B; Khalil M; Saadeh R; Teunissen C; Tumani H; Villar LM; Willrich MAV; Zetterberg H; Deisenhammer F
    Mult Scler; 2023 Feb; 29(2):169-181. PubMed ID: 36453167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid immunoglobulin light chain ratios predict disease progression in multiple sclerosis.
    Rathbone E; Durant L; Kinsella J; Parker AR; Hassan-Smith G; Douglas MR; Curnow SJ
    J Neurol Neurosurg Psychiatry; 2018 Oct; 89(10):1044-1049. PubMed ID: 29743290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concentrations of immunoglobulin free light chains in cerebrospinal fluid predict increased level of brain atrophy in multiple sclerosis.
    Nazarov V; Makshakov G; Kalinin I; Lapin S; Surkova E; Mikhailova L; Gilburd B; Skoromets A; Evdoshenko E
    Immunol Res; 2018 Dec; 66(6):761-767. PubMed ID: 30635824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Intrathecal Free Light Chain Synthesis: Comparison of Different Quantitative Methods with the Detection of Oligoclonal Free Light Chains by Isoelectric Focusing and Affinity-Mediated Immunoblotting.
    Zeman D; Kušnierová P; Švagera Z; Všianský F; Byrtusová M; Hradílek P; Kurková B; Zapletalová O; Bartoš V
    PLoS One; 2016; 11(11):e0166556. PubMed ID: 27846293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement.
    Hegen H; Arrambide G; Gnanapavan S; Kaplan B; Khalil M; Saadeh R; Teunissen C; Tumani H; Villar LM; Willrich MAV; Zetterberg H; Deisenhammer F
    Mult Scler; 2023 Feb; 29(2):182-195. PubMed ID: 36527368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF Free Light Chains as a Marker of Intrathecal Immunoglobulin Synthesis in Multiple Sclerosis: A Blood-CSF Barrier Related Evaluation in a Large Cohort.
    Senel M; Mojib-Yezdani F; Braisch U; Bachhuber F; Lewerenz J; Ludolph AC; Otto M; Tumani H
    Front Immunol; 2019; 10():641. PubMed ID: 30984199
    [No Abstract]   [Full Text] [Related]  

  • 13. Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity-a cohort study.
    Hegen H; Berek K; Bsteh G; Auer M; Altmann P; Di Pauli F; Grams A; Milosavljevic D; Ponleitner M; Poskaite P; Schnabl C; Wurth S; Zinganell A; Berger T; Walde J; Deisenhammer F
    EBioMedicine; 2023 May; 91():104573. PubMed ID: 37086651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The association of intrathecal production of immunoglobulin free light chains and progression of multiple sclerosis].
    Makshakov GS; Nazarov VD; Totolyan NA; Lapin SV; Mazing AV; Emanuel VL; Krasnov VS; Shumilina MV; Skoromets AA; Evdoshenko EP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10. Vyp. 2):4-10. PubMed ID: 29359727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Levels of Cerebrospinal Fluid Kappa Free Light Chains Relate to IgM Intrathecal Synthesis and Might Have Prognostic Implications in Relapsing Multiple Sclerosis.
    Castillo-Villalba J; Gil-Perotín S; Gasque-Rubio R; Cubas-Nuñez L; Carratalà-Boscà S; Alcalá C; Quintanilla-Bordás C; Pérez-Miralles F; Ferrer C; Cañada Martínez A; Tortosa J; Solís-Tarazona L; Campos L; Leivas A; Laíz Marro B; Casanova B
    Front Immunol; 2022; 13():827738. PubMed ID: 35330910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of κ free light chains in cerebrospinal fluid as a biomarker in multiple sclerosis diagnosis: development of a diagnosis algorithm.
    Valencia-Vera E; Martinez-Escribano Garcia-Ripoll A; Enguix A; Abalos-Garcia C; Segovia-Cuevas MJ
    Clin Chem Lab Med; 2018 Mar; 56(4):609-613. PubMed ID: 29087953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of sensitivities and specificities of cerebrospinal fluid free light chains to diagnose multiple sclerosis- a multicentric case-control study.
    Thevarkalam M; Krishnan S; Shanmughan LI; Mathai A; Leelamani JV; Kannoth S; Bhaskaran R; Iype T; Panda S
    Mult Scler Relat Disord; 2023 Jun; 74():104717. PubMed ID: 37062197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid free light chains compared to oligoclonal bands as biomarkers in multiple sclerosis.
    Gaetani L; Di Carlo M; Brachelente G; Valletta F; Eusebi P; Mancini A; Gentili L; Borrelli A; Calabresi P; Sarchielli P; Ferri C; Villa A; Di Filippo M
    J Neuroimmunol; 2020 Feb; 339():577108. PubMed ID: 31743879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation and meta-analysis of kappa index biomarker in multiple sclerosis diagnosis.
    Menéndez-Valladares P; García-Sánchez MI; Adorna Martínez M; García De Veas Silva JL; Bermudo Guitarte C; Izquierdo Ayuso G
    Autoimmun Rev; 2019 Jan; 18(1):43-49. PubMed ID: 30408586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Free light chains in the cerebrospinal fluid. Comparison of different methods to determine intrathecal synthesis.
    Hegen H; Walde J; Milosavljevic D; Aboulenein-Djamshidian F; Senel M; Tumani H; Deisenhammer F; Presslauer S
    Clin Chem Lab Med; 2019 Sep; 57(10):1574-1586. PubMed ID: 31112501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.